OncoMatch/Clinical Trials/NCT07203378
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
Is NCT07203378 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for metastatic breast cancer.
The goal of this study is to test the efficacy of using a 12-week, home-based, unsupervised aerobic and resistance training exercise program for changes in cancer-related fatigue in patients with metastatic breast cancer who are receiving Enhertu.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: HER2 (ERBB2) overexpression
Patients with High-Risk HER-2 + breast cancer after completion of neoadjuvant chemotherapy requiring adjuvant Enhertu are allowed at the discretion of the treating physician.
Prior therapy
Must have received: antibody-drug conjugate (Enhertu)
Has received 3 or 4 cycles of Enhertu and is expected to continue treatment for at least 12 weeks.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute at University of Utah · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify